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Chenodeoxycholic acid suppresses the activation of
acetyl-coenzyme A carboxylase-a gene transcription by
the liver X receptor agonist T0-901317
Saswata Talukdar, Sushant Bhatnagar, Sami Dridi, and F. Bradley Hillgartner1
Department of Biochemistry, School of Medicine, West Virginia University, Morgantown, WV 26506
Abstract The therapeutic utility of liver X receptor (LXR)
agonists in treating atherosclerosis is limited by an un-
desired accumulation of triglycerides in the blood and liver.
This effect is caused by an increase in the transcription
of genes involved in fatty acid synthesis. Here, we show
that the primary bile acid, chenodeoxycholic acid (CDCA),
antagonizes the stimulatory effect of the synthetic LXR
agonist, T0-901317, on the expression of acetyl-coenzyme
A carboxylase-a (ACCa) and other lipogenic enzymes in
chick embryo hepatocyte cultures. CDCA inhibits T0-901317-
induced ACCa transcription by suppressing the enhancer
activity of a LXR response unit (2101 to 271 bp) that binds
LXR and sterol-regulatory element binding protein-1
(SREBP-1). We also demonstrate that CDCA decreases the
expression of SREBP-1 in the nucleus and the acetylation of
histone H3 and H4 at the ACCa LXR response unit. The
CDCA-mediated reduction in ACCa expression is associated
with a decrease in the expression of peroxisomeproliferator-
activated receptor g coactivator-1a (PGC-1a) and small het-
erodimer partner and an increase in the expression of
fibroblast growth factor-19 (FGF-19). Ectopic expression of
FGF-19 decreases T0-901317-induced ACCa expression. In-
hibitionofp38mitogen-activatedproteinkinase (MAPK)and/
or extracellular signal-regulated kinase (ERK) suppresses the
effects of CDCA on the expression of ACCa, SREBP-1, PGC-
1a, and FGF-19. These results demonstrate that CDCA
inhibits T0-901317-induced ACCa transcription by suppress-
ing the activity of LXR and SREBP-1. We postulate that p38
MAPK, ERK, PGC-1a, and FGF-19 are components of the
signaling pathway(s) mediating the regulation of ACCa gene
transcription by CDCA.—Talukdar, S., S. Bhatnagar, S. Dridi,
and F. B. Hillgartner. Chenodeoxycholic acid suppresses the
activation of acetyl-coenzyme A carboxylase-a gene transcrip-
tion by the liver X receptor agonist T0-901317. J. Lipid Res.
2007. 48: 2647–2663.
Supplementary key words fatty acid synthesis & sterol-regulatory
element binding protein & fibroblast growth factor-19 & peroxisome
proliferator-activated receptor g coactivator-1a & p38 mitogen-activated
protein kinase & extracellular signal-regulated kinase & small heterodi-
mer partner & farnesoid X receptor
The liver X receptors (LXRs) have emerged as impor-
tant regulators of genes involved in lipid and lipoprotein
metabolism in higher vertebrates. LXRs were initially iden-
tified as orphan members of the nuclear receptor super-
family (1, 2). Two isoforms exist with different expression
patterns. LXRa is expressed at high levels in liver, adi-
pose tissue, and macrophages, whereas LXRb is expressed
ubiquitously (2, 3). The majority of the LXR proteins are
localized in the nucleus and require heterodimerization
with the retinoid X receptor (RXR) to bind DNA and
regulate transcription (2). LXR&RXR heterodimers bind
cis-acting sequences that are composed of hexameric half-
sites arranged as direct repeats with a 4 bp spacer sep-
arating the half-sites (20. These sequences are referred to
as liver X receptor response elements (LXREs). Ligand-
bound nuclear receptors activate transcription by recruit-
ing auxiliary transcriptional regulatory proteins referred
to as coactivators (4). Examples of coactivators of LXR in-
clude steroid receptor coactivator-1 (5) and peroxisome
proliferator-activated receptor g coactivator-1a (PGC-1a)
(6). Coactivators facilitate the ability of LXR to activate
transcription by interacting directly with the basal tran-
scriptional machinery, by modulating interactions be-
tween LXR and the basal transcriptional machinery, and
by modifying chromatin structure.
The screening of organic tissue extracts using a cell-
based reporter assay has led to the discovery that oxysterols
are the endogenous ligands that bind and activate LXRa
and LXRb (7, 8). The most potent endogenous LXR
ligands are 24(S)-hydroxycholesterol, 22(R)-hydroxycho-
lesterol, and 24(S)-epoxycholesterol. In avians and mam-
mals, LXR agonists activate a battery of genes involved in
cholesterol efflux (ABCA1, ABCG1, ABCG5, and ABCG8),
cholesterol clearance (cholesteryl ester transfer protein
and apolipoprotein E), and cholesterol catabolism (cho-
lesterol 7a-hydroxylase) (reviewed in Refs. 9, 10). Because
oxysterols are produced in proportion to cellular choles-
terol content, LXRs have been proposed to function as
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sensors in a feed-forward pathway that stimulates reverse
cholesterol transport and cholesterol excretion in re-
sponse to high cholesterol levels in the diet. Consistent
with this proposal, mice lacking the LXRa and/or LXRb
gene exhibit diminished cholesterol excretion and in-
creased cholesterol levels in the blood and liver when fed
a high-cholesterol diet (11, 12).
In avians and mammals, LXR agonists also activate
the transcription of genes involved in triglyceride synthe-
sis, including ATP-citrate lyase, FAS, stearoyl-coenzyme A
desaturase-1 (SCD1), and acetyl-coenzyme A carboxylase-a
(ACCa) (13–15). In the case of ACCa, we have shown that
this effect is mediated by the activation of LXR&RXR het-
erodimers bound to the ACCa gene and by the increased
expression of sterol-regulatory element binding protein-1
(SREBP-1) that binds a site adjacent to the ACCa LXRE
and enhances the ability of LXR&RXR to activate ACCa
transcription (15). LXR agonists increase the expression of
SREBP-1 by activating a LXRE on the SREBP-1 gene (16).
HMG-CoA reductase inhibitors (statins) are currently
the first-line agents to treat and prevent atherosclerosis
in humans. Unfortunately, statins are not effective at re-
ducing circulating cholesterol and LDL levels in a sig-
nificant fraction of patients with dyslipidemia (17). This
has triggered a strong interest in the development of new
pharmacological approaches to achieve atheroprotection.
LXR agonists represent one such approach, because these
compounds stimulate reverse cholesterol transport and
cholesterol excretion. Several laboratories have identified
nonsteroidal, synthetic compounds that are more effective
than endogenous oxysterols at stimulating LXR activity
(14, 18). The atheroprotective properties of two of these
synthetic LXR agonists, designated T0-901317 {N -(2,2,2-
trifluoro-ethyl)-N-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoro-
methyl-ethyl)-phenyl]benzenesulfonamide} and GW3965
{2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphe-
nylethyl)amino]propoxy}-phenyl)acetic acid}, have been
evaluated in murine models of atherosclerosis. Oral admin-
istration of T0-901317 or GW3965 to mice lacking the
LDL receptor or apolipoprotein E stimulates an increase
in blood HDL levels and reverses the formation of ath-
erosclerotic lesions in the aorta (19, 20). LXR agonists also
improve insulin sensitivity in murine models of type 2 di-
abetes (21, 22). These exciting findings are tempered by
the observation that treatment with T0-901317 or GW3965
also causes hypertriglyceridemia and the development of
a fatty liver (10, 14, 23). These undesired effects of T0-
901317 and GW3965 are attributable to an increase in
hepatic fatty acid synthesis. One approach to overcome
this problem is to activate another signaling pathway that
selectively inhibits the effect of LXR agonists on lipogenic
gene transcription without altering their ability to stimu-
late genes involved in reverse cholesterol transport.
In the present study, we report that chenodeoxycholic
acid (CDCA) inhibits the ability of T0-901317 to increase
the expression of ACCa and other lipogenic enzymes in
primary cultures of chick embryo hepatocytes. Interestingly,
CDCA does not alter the stimulatory effect of T0-901317
on the expression of ABCA1, a key protein controlling
reverse cholesterol transport. We also demonstrate that
CDCA decreases ACCa gene transcription by inhibiting
the activity of LXR&RXR and SREBP-1 on the ACCa gene
and that p38mitogen-activated protein kinase (MAPK) and
extracellular signal-regulated kinase (ERK) are compo-
nents of the signaling pathway(s) mediating this response.
EXPERIMENTAL PROCEDURES
Cell culture
Chick embryo hepatocytes were isolated as described previ-
ously (24). These cells were incubated in serum-free Waymouth’s
medium MD752/1 containing penicillin (60 mg/ml) and strep-
tomycin (100 mg/ml) on untreated Petri dishes at 40jC in a
humidified atmosphere of 5% CO2 and 95% air. Hormone and
other additions were as described in the figure legends. Concen-
trated stocks of T0-901317 and CDCA were dissolved in ethanol
and water, respectively.
Rathepatocyteswere isolatedbyamodificationof the technique
of Seglen (25) as described by Stabile et al. (26). These cells were
incubated in serum-free Waymouth’s mediumMD752/1 contain-
ing 20 mM HEPES, pH 7.4, 0.5 mM serine, 0.5 mM alanine,
penicillin (100 mg/ml), streptomycin (100 mg/ml), and gentami-
cin (50mg/ml) on 60mmPrimaria dishes at 37jC in a humidified
atmosphere of 5% CO2 and 95% air. The medium contain-
ing treatments [T0-901317 (6 mM) in the absence or presence of
CDCA (75 mM)] was added after 18 h of culture.
Measurement of fatty acid synthesis
The rate of de novo fatty acid synthesis was measured in chick
embryo hepatocyte cultures using the tritiated water method
(27). Cells were incubated with 0.2 mCi/ml 3H2O during the last
3 h of a 24 h treatment period with T0-901317 in the absence
or presence of CDCA. After removal of the incubation medium,
the cells were harvested in 8 N KOH and transferred to screw-cap
tubes. An equal volume of ethanol was added, and the tubes were
heated in a boiling-water bath for 2 h. Nonsaponifiable lipids
were extracted three times with petroleum ether and discarded.
The aqueous phase was acidified with 0.5 volume of 12 N HCl,
and saponifiable lipids were extracted three times with petro-
leum ether. The pooled petroleum extracts were washed once
with 0.5% acetic acid and dried under a stream of N2.
3H radio-
activity was determined by scintillation counting. Fatty acid
synthesis rates were calculated as described (27).
Isolation of RNA and quantitation of mRNA levels
Medium was removed and total RNA was extracted from
hepatocytes by the guanidinium thiocyanate-phenol-chloroform
method (28). In some experiments, the abundance of mRNA
encoding ACCa, FAS, SCD1, ATP-citrate lyase, ABCA1, SREBP-1,
SREBP cleavage-activating protein (SCAP), insulin-induced
gene-1 (Insig-1), and insulin-induced gene-2 (Insig-2) was mea-
sured by Northern analysis as described previously (15). In
other experiments, the abundance of mRNA encoding ACCa,
ABCA1, fibroblast growth factor-19 (FGF-19), LXRa, PGC-1a,
PGC-1b, nuclear T3 receptor-a (TRa), and small heterodimer
partner (SHP) was measured by quantitative real-time PCR anal-
ysis using the Qiagen Quantitect SYBR green RT-PCR system.
Samples of DNase I-treated RNA (100 ng) were analyzed in trip-
licate according to the manufacturer’s instructions. PCR was
performed on 96-well plates using a Bio-Rad iCycler iQ. The
relative amount of mRNA was calculated using the comparative
threshold cycle method. 18S rRNA was used as a reference gene.
2648 Journal of Lipid Research Volume 48, 2007
Amplification of specific transcripts was confirmed by analyzing
the melting curve profile at the end of each run and by deter-
mining the size of the PCRproducts using agarose electrophoresis
and ethidium bromide staining.
Primer sets for each gene were designed using PrimerQuest
software from Integrated DNA Technologies. PCR primers used
were as follows: chicken ACCa, sense, 5¶-CACTTCGAGGCGAAA-
AACTC-3¶; antisense, 5¶-GGAGCAAATCCATGACCACT-3¶; chicken
FGF-19, sense, 5¶-TGGGAATTCAGCATGTGGGTAGGA-3¶; anti-
sense, 5¶-TTTCAAACGGTGCAGGATGAAGCC-3¶; chicken
LXRa, sense, 5¶-ACTCAACTCAGCACACAGGACCAT-3¶; anti-
sense, 5¶-AGCTTCTTCAGCCGAATCTGCTCT-3¶; chicken PGC-
1a, sense, 5¶-TCAGCATGAAAGGCTGAAGAGGGA-3¶; antisense,
5¶-TAGCTGTCTCCATCATCCCGCAAA-3¶; chicken PGC-1b, sense,
5¶-TCAGAAAGCCATGAAGAAGCACCC-3¶; antisense,5¶-TGATGCC-
ATCCTTCCACACCATCT-3¶; chicken TRa, sense, 5¶-TTCTCAGCA-
GGAGTGCTCGC-3¶; antisense, 5¶-GGCTTCTGTTCCATTCACCGCA-
AT-3¶; chicken SHP, sense, 5¶-ACACCTTCTGGAGCCTGGATTTGA-3¶;
antisense, 5¶-TGAGCTCAACAATGTCTGCGTTGC-3¶; chicken 18S,
sense, 5¶-CGGAGAGGGAGCCTGAGAA-3¶; antisense, 5¶-CGCCAGC-
TCGATCCCAAGA-3¶; rat ACCa, sense, 5¶-AGGGCAAAGGGACTG-
GTGTTCAGAT-3¶; antisense, 5¶-GCCAACGGAGATGGTTCATCC-
ATTA-3¶; rat ABCA1, sense, 5¶-CCCAGAGCAAAAAGCGACTC-3¶;
antisense, 5¶-GGTCATCATCACTTTGGTCCTTG-3¶; rat FAS, sense,
5¶-TGCAACTGTGCGTTAGCCACC-3¶; antisense, 5¶-TGTTTCAGGGG-
AGAAGAGACC-3¶; and rat SCD1, sense, 5¶-AGCTCAGCCAAATGCTG-
TGTTGTC-3¶; antisense, 5¶-TGCCTTGATCAGTCACAGACACCT-3¶.
Plasmids
Reporter plasmids are named by designating the 5¶ and 3¶ ends
of the ACCa DNA fragment relative to the transcription start site
of promoter 2. A series of 5¶ deletions and 3¶ deletions of ACCa
promoter 2 in the context of p[ACC22054/1274] chloram-
phenicol acetyltransferase (CAT) have been described previously
(29). An ACCa promoter construct containing a mutation of the
SRE between 279 and 272 bp in the context of p[ACC2108/
1274]CAT has been described (30). p[ACC2108/266]TKCAT,
p[ACC284/266]TKCAT, and pTKCAT constructs containing
mutations in the 2108 to 266 bp ACCa fragment have been
described (30). To construct the adenoviral expression vector
pAdEasy-FGF-19, the coding sequence of chicken FGF-19 was
subcloned into the shuttle vector pShuttle-CMV to form pShuttle-
CMV-FGF-19. The CMV promoter-FGF-19 transcription unit was
inserted into pAdEasy-1 via homologous recombination in the
bacterial strain BJ5183-AD-1. Adenoviruses were propagated in
HEK-293 cells and purified by CsCl gradient centrifugation.
Transient transfection
Chick embryo hepatocytes were transfected as described by
Zhang, Yin, and Hillgartner (29). Briefly, cells were isolated and
incubated on 60 mm Petri dishes. At 6 h of incubation, the
medium was replaced with one containing 10 mg of Lipofectin
(Invitrogen), 1.5 mg of p[ACC22054/1274]CAT or an equimo-
lar amount of another reporter plasmid, and pBluescript KS(1)
to bring the total amount of transfected DNA to 1.5 mg per plate.
At 18 h of incubation, the transfection medium was replaced
with fresh medium containing T0-901317 (6 mM) with or with-
out CDCA (75 mM). At 66 h of incubation, chick embryo hepa-
tocytes were harvested, and cell extracts were prepared as
described (31). CAT activity (32) and protein (33) were assayed
by the indicated methods.
Western blot analysis
Nuclear extracts, membrane extracts, and total cell lysates
were prepared from chick embryo hepatocytes as described
(15, 30). Equal amounts of denatured protein were subjected to
electrophoresis on 10% SDS-polyacrylamide gels and then trans-
ferred to polyvinylidene difluoride membranes (Millipore) using
an electroblotting apparatus (Bio-Rad Laboratories, Hercules,
CA). The blots were blocked in TBST (10 mM Tris-HCl, pH 8.0,
150 mM NaCl, and 0.1% Tween) containing 5% nonfat dry milk
for 1 h at room temperature and then incubated with primary
antibody diluted 1:2,000 in TBST containing 5% BSA. After in-
cubation with primary antibody for 12 h at 4jC, the blots were
washed in TBST. Next, the blots were incubated with secondary
antibody conjugated to horseradish peroxidase ( Jackson Immuno-
Research) diluted 1:5,000 in TBST and 5% nonfat dry milk for
1 h at room temperature. After washing with TBST, antibody-
protein complexes on blots were detected using enhanced chemi-
luminescence (Amersham Biosciences). Chemiluminescence on
the blots was visualized using a FluorChem 8000 imager (Alpha
Innotech Corp.), and signals were quantified using FluorChem
V200 software. A mouse monoclonal antibody against SREBP-1
(IgG-2A4) was obtained from the American Type Culture Col-
lection (Manassas, VA). Antibodies against phosphorylated p38
MAPK (Thr180/Tyr182), phosphorylated ERK (Tyr183/185), phos-
phorylated c-Jun N-terminal kinase ( JNK) (Thr183/Tyr185), phos-
phorylated Raf (Ser259), phosphorylated MAPK kinase 3/6
(MKK3/6) (Ser189/207), phosphorylated MAPK/ERK kinase
(MEK1/2) (Ser221), total p38 MAPK, total ERK, total JNK, and
ACCa were obtained from Cell Signaling Technology. The anti-
body against ABCA1 was obtained from Novus.
Gel mobility shift analysis
Nuclear extracts were prepared from hepatocytes incubated
with or without CDCA in the presence of T0-901317 (30). A
double-stranded oligonucleotide containing the ACCa LXRE/
T3 response element (T3RE) (2108 to 282 bp relative to the
transcription initiation site of ACCa promoter 2) was labeled by
filling in overhanging 5¶ ends using the Klenow fragment of
Escherichia coli DNA polymerase in the presence of [a-32P]dCTP.
Binding reactions were carried out as described previously (29).
DNA and DNA-protein complexes were resolved on 6% non-
denaturing polyacrylamide gels at 4jC in 50 mM Tris (pH 8.8)
and 50mM glycine. After electrophoresis, the gels were dried and
subjected to storage phosphor autoradiography.
Histone acetylation
The extent of histone acetylation on ACCa promoter 2 was
measured using a chromatin immunoprecipitation (ChIP) assay.
The procedure for this assay was the same as that described by Yin
et al. (34). ChIP was carried out with antibodies against acetyl-
histone H3 (06-599) and acetyl-histone H4 (06-866) (Upstate Bio-
technology). Precipitated DNA was analyzed by PCR using Taq
DNA polymerase (New England Biolabs) and primers specific for
the ACCa and SCD1 promoters (15). Amplified products were
subjected to electrophoresis on 2% agarose gels and visualized by
ethidium bromide staining.
RESULTS
CDCA inhibits the activation of lipogenic enzyme
expression by the LXR agonist T0-901317
The development of hyperlipidemia and fatty liver in
avians and mammals treated with LXR agonists is me-
diated by an increase in the expression of lipogenic en-
zymes in liver (14, 15, 23, 35). Accordingly, we wanted to
develop a combination strategy that suppressed the
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undesired effect of LXR agonists on lipogenic genes
without altering the beneficial effect of LXR agonists on
genes controlling reverse cholesterol transport.We initially
tested the ability of cAMP and hexanoate to suppress
the stimulatory effect of T0-901317 on lipogenic enzyme
expression, as previous studies showed that these com-
pounds inhibited the increase in ACCa and FAS gene
transcription caused by nuclear triiodothyronine (T3) re-
ceptor activation (36–39). Of these compounds, hexanoate
(1 mM) was effective at suppressing T0-901317-induced
expression of ACCa mRNA and FAS mRNA in chick em-
bryo hepatocyte cultures (data not shown). However, treat-
ment with hexanoate also inhibited T0-901317-induced
expression of ABCA1, thus negating the usefulness of this
compound in developing a combination strategy.
We next investigated the ability of CDCA to suppress
the effect of T0-901317 on lipogenic enzyme expression,
because previous studies showed that oral administration
of CDCA reduced hypertriglyceridemia in diabetic ham-
sters and humans with cholesterol gallstones (40, 41).
Treatment with CDCA suppressed the stimulatory effect of
T0-901317 on the abundance of mRNAs encoding ACCa,
FAS, and SCD1 (Fig. 1A). The effect of CDCA on T0-
901317-induced expression of ACCa, FAS, and SCD1 was
dose-dependent, with a maximal inhibition (61–68%) ob-
served at 50 mM. The CDCA-mediated reduction in ACCa
mRNA abundance was associated with a decrease (55%) in
ACCa protein concentration (Fig. 1B). In contrast to the
results for lipogenic enzymes, CDCA enhanced the stim-
ulatory effect of T0-901317 on the abundance of the
mRNA encoding ABCA1, a key gene controlling reverse
cholesterol transport (Fig. 1A). CDCA treatment did not
alter the stimulatory effect of T0-901317 on ABCA1 pro-
tein concentration (Fig. 1B). In the absence of T0-901317,
CDCA treatment had no effect on the abundance of
mRNAs encoding ACCa, FAS, SCD1, and ABCA1. Thus,
activation of a CDCA signaling pathway(s) selectively in-
hibits the effect of T0-901317 on the expression of lipo-
genic enzymes in avian hepatocytes.
We next asked whether CDCA altered LXR signaling
activity in a mammalian cell culture system. Treatment of
rat hepatocyte cultures with CDCA (75 mM) suppressed
the stimulatory effect of T0-901317 on the abundance of
mRNAs encoding ACCa, FAS, and SCD1 by 33–56% (data
not shown). In contrast, CDCA treatment had no effect
on T0-901317-induced expression of ABCA1 mRNA. Thus,
CDCA inhibition of lipogenic enzyme expression is con-
served across different classes of animals.
Oral administration of bile acids causes a reduction in
serum triglyceride levels in animals treated with T0-901317
(42). To investigate whether this effect is mediated by
a decrease in hepatic lipogenesis, the rate of fatty acid
synthesis was measured in chick embryo hepatocytes in-
cubated with T0-901317 in the absence and presence of
CDCA. Treatment of hepatocytes with T0-901317 for 24 h
caused a 4.3-fold increase in the rate of fatty acid synthesis
(Fig. 2A), and the addition of CDCA (75 mM) blocked this
effect. We also measured hepatic triglyceride production
in chick embryo hepatocytes by monitoring the triglycer-
Fig. 1. Chenodeoxycholic acid (CDCA) suppresses the activa-
tion of lipogenic enzyme expression by the liver X receptor (LXR)
agonist T0-901317. Chick embryo hepatocytes were isolated and
incubated in serum-free Waymouth’s medium containing insulin
(50 nM). At 18 h of incubation, the medium was changed to
one of the same composition supplemented with or without T0-
901317 (6 mM) in the absence or presence of CDCA (0–75 mM).
Total RNA and cell lysates were prepared after 28 and 48 h of
treatment, respectively. A: The abundance of mRNA encoding
acetyl-coenzyme A carboxylase-a (ACCa), FAS, stearoyl-coenzyme
A desaturase-1 (SCD1), and ABCA1 was measured by Northern
analysis. Levels of mRNA in cells treated without T0-901317 and
CDCA were set at 1, and the other values were adjusted propor-
tionately. Values are means 6 SEM of four experiments. Hy-
bridization signals from a representative experiment are shown
for each mRNA. Asterisks indicate that the mean is significantly
(P , 0.05) different from that of cells treated with T0-901317
in the absence of CDCA. B: The abundance of ACCa protein
and ABCA1 protein in total cell lysates was measured by
Western analysis. The data are representative of three indepen-
dent experiments.
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ide concentration of the culture medium. In accordance
with the results from the fatty acid synthesis experiments,
treatment with CDCA blocked the ability of T0-901317
to increase the triglyceride concentration of the culture
medium (Fig. 2B). These findings suggest that alterations
in hepatic lipogenic enzyme expression and triglyceride
secretion play a role in mediating the inhibitory effect of
CDCA on serum triglyceride levels in intact animals.
Identification of cis-acting sequences that mediate
the effect of CDCA on T0-901317-induced
ACCa transcription
To determine the mechanism by which CDCA sup-
pressed the increase in lipogenic enzymeexpression caused
by T0-901317, transient transfection experiments were per-
formed to identify cis-acting elements conferring CDCA
regulation of gene transcription. In conducting these
studies, we focused on the chicken ACCa gene, as the
mechanism mediating the stimulatory effect of T0-901317
on the transcription of this gene is well characterized. T0-
901317 increases ACCa transcription by activating
LXR&RXR complexes bound to a composite LXRE/T3RE
(2101 to286bp)andby increasing thebindingof SREBP-1
to an adjacent sterol regulatory element (SRE) (282 to
271 bp) in the more downstream promoter (promoter 2)
of the ACCa gene (15). SREBP-1 enhances the ability
of ligand-bound LXR&RXR complexes to activate ACCa
transcription. To determine the role of the ACCa LXRE,
ACCa SRE, and other sequences in the ACCa gene in
mediating the inhibitory effect of CDCA on T0-901317-
inducedACCa transcription, a series of reporter constructs
containing 5¶ deletions of ACCa promoter 2 were transfec-
ted into chick embryo hepatocytes. In cells transfected
with a reporter construct containing 2,054 bp of 5¶ flanking
DNA, CDCA treatment decreased T0-901317-induced pro-
moter activity by 58% (Fig. 3A). 5¶ deletion of ACCa se-
quences to 2391, 2136, and 2108 bp had no effect on
CDCA responsiveness. Deletion of ACCa sequences con-
taining the LXRE/T3RE (2108 to 284 bp) abolished the
CDCA-mediated inhibition of ACCa transcription. This
deletion also decreased T0-901317-induced ACCa pro-
moter activity by 54%. Further deletion to 241 bp had
no effect on CDCA responsiveness. Mutation of the SRE
(280 to 271 bp) in the context of 108 bp of 5¶ flanking
DNA decreased CDCA responsiveness by 61%. These re-
sults suggest that the ACCa LXRE is required for CDCA-
mediated inhibition of ACCa transcription and that the
ACCa SRE enhances the ability of the LXRE to confer
inhibition of ACCa transcription by CDCA.
To further investigate the role of the ACCa LXRE and
SRE in mediating the effect of CDCA on ACCa transcrip-
tion, transfection analyses were carried out using con-
structs containing fragments of the ACCa gene linked to
a heterologous promoter. The minimal promoter of the
thymidine kinase (TK) gene was unresponsive to CDCA
(Fig. 3B). When a DNA fragment containing both the
ACCa LXRE and ACCa SRE (2108 to 266 bp) was linked
to the TK promoter, treatment with CDCA caused a 60%
decrease in promoter activity. Mutation of the ACCa SRE
in the context of the ACCa 2108 to 266 bp fragment
caused a 38% decrease in CDCA responsiveness. When a
DNA fragment containing the ACCa SRE alone (284 to
266 bp) was appended to the TK promoter, CDCA treat-
ment had no effect on promoter activity. These results
confirm that the ACCa LXRE alone is effective at con-
ferring the inhibitory effect of CDCA on ACCa promoter
activity and that the presence of the ACCa SRE enhances
the ability of the ACCa LXRE to confer CDCA regulation.
Thus, CDCA inhibits T0-901317-induced ACCa transcrip-
tion by suppressing the ability of the LXRE and SRE to
activate transcription.
CDCA suppresses the stimulatory effect of T0-901317
on the abundance of mature SREBP-1
SREBP-1 is synthesized as a 125 kDa precursor protein
that is anchored to the endoplasmic reticulum (ER) (43).
Fig. 2. CDCA suppresses the stimulatory effect of T0-901317 on
fatty acid synthesis and triglyceride production. Chick embryo
hepatocytes were plated on 90 mm Petri dishes (13 107 cells/dish)
in Waymouth’s medium containing insulin. At 18 h of incubation,
the medium was changed to one of the same composition sup-
plemented with or without T0-901317 in the absence and presence
of CDCA (75 mM). A: Between 39 and 42 h of incubation, cells were
incubated with 3H2O and the incorporation of tritium into fatty
acids was measured as described in Experimental Procedures. B:
At 42 h of incubation, the concentration of triglyceride in the
culture medium was measured using a spectrophotometric assay.
Data are means6 SEM of three experiments. Asterisks indicate that
the mean is significantly (P , 0.05) higher than that of cells
incubated with T0-901317 and CDCA.
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To become transcriptionally active, precursor SREBP-1 is
translocated to the Golgi, where it is cleaved by two pro-
teases, resulting in the release of the N-terminal seg-
ment of SREBP-1, referred to as mature SREBP-1. Mature
SREBP-1 is transported into the nucleus, where it binds
to target genes and activates transcription. T0-901317
increases ACCa transcription, in part, by increasing the
expression of mature SREBP-1 (15). This observation
prompted us to investigate whether the CDCA inhibited
ACCa SRE activity by suppressing the stimulatory effect
of T0-901317 on the concentration of mature SREBP-1.
In chick embryo hepatocytes previously incubated with
T0-901317 for 24 h, the addition of CDCA caused a rapid
decrease (<2 h) in the concentration of mature SREBP-1,
with a maximal inhibition (36%) observed after 12 h of
treatment (Fig. 4). These changes in mature SREBP-1 con-
centration were closely associated with alterations in ACCa
mRNA abundance. These results suggest that changes in
mature SREBP-1 concentration play a role inmediating the
decrease in ACCa SRE activity caused by CDCA.
To investigate the mechanism mediating the reduc-
tion in mature SREBP-1 levels caused by CDCA, the effect
of CDCA on the concentration of precursor SREBP-1 pro-
tein and SREBP-1 mRNA was determined in hepatocytes
previously treated with T0-901317 for 24 h. Addition of
CDCA caused a rapid (<6 h) and sustained (>24 h) in-
crease in the abundance of precursor SREBP-1 (Fig. 4).
Thus, the decrease in the concentration of mature SREBP-1
caused by CDCA is not associated with a reduction in the
concentration of precursor SREBP-1, suggesting that a post-
translational process is involved in mediating the effect of
CDCA on mature SREBP-1 levels. Further evidence that
a posttranslational process plays a role in mediating the
actions of CDCA on mature SREBP-1 levels is provided by
the observation that treatment with CDCA has no effect on
the abundance of SREBP-1 mRNA (Fig. 4).
One posttranslational process that controls the abun-
dance of mature SREBP-1 is the proteolytic cleavage of
precursor SREBP-1 to mature SREBP-1 (43). This process
is controlled by two ER proteins, SCAP and Insig. SCAP
binds to SREBP-1 and escorts it from the ER to the Golgi.
Insig binds to SCAP and retains the SCAP-SREBP-1 com-
plex in the ER, thus preventing the processing of SREBP-1.
There are two isoforms of Insig (Insig-1 and Insig-2) that
are encoded by separate genes. Insulin decreases the
expression of Insig-2 in liver, and this effect has been
proposed to play a role in mediating the stimulatory ef-
fect of insulin on SREBP-1 processing (44). To investigate
whether changes in Insig expression play a role in me-
diating the inhibitory effect of CDCA on mature SREBP-1
levels, the effect of CDCA on the abundance of Insig-1
mRNA and Insig-2 mRNA was determined. In hepato-
cytes incubated with T0-901317 for 24 h, the addition of
CDCA for 2 h caused a 1.9-fold increase in Insig-1 mRNA
Fig. 3. A LXR response unit composed of a liver X receptor response element (LXRE) and a sterol-regulatory element (SRE) confers the
inhibitory effect of CDCA on T0-901317-induced ACCa gene transcription. Chick embryo hepatocytes were transiently transfected with
reporter constructs containing portions of ACCa promoter 2 linked to the chloramphenicol acetyltransferase (CAT) gene. After trans-
fection, cells were treated with or without T0-901317 in the absence and presence of CDCA for 48 h. Cells were then harvested, extracts
prepared, and chloramphenicol acetyltransferase (CAT) assays performed. A: Effect of mutations of the 5¶ flanking region of ACCa
promoter 2 on the CDCA regulation of transcriptional activity. The number at the left of each construct is the 5¶ end of ACCa DNA in
nucleotides relative to the transcription initiation site of promoter 2. The 3¶ end of each construct is 1274 bp. The locations of the LXRE
(2101 to286 bp) and the SRE (280 to271 bp) are indicated by vertical lines. A block mutation of the SRE is indicated by an X through the
vertical line. The CAT activity of cells transfected with p[ACC2108/1274]CAT and treated with T0-901317 was set at 1, and the other
activities were adjusted proportionately. B: Ability of the ACCa LXRE and SRE to confer CDCA regulation on the minimal thymidine kinase
(TK) promoter in TKCAT. A block mutation of the SRE is indicated by an X across the box representing the SRE. CAT activity of cells
transfected with TKCAT and treated with T0-901317 was set at 1, and the other activities were adjusted proportionately. The effect of CDCA
is the CAT activity of cells treated with T0-901317 and CDCA expressed as a percentage of that in cells treated with T0-901317. The effect
of CDCA was calculated for individual experiments and then averaged. The results are means 6 SEM of five experiments. Significant
difference between means within a column (P , 0.05) are as follows: a versus p[ACC2108/1274]CAT; b versus p[ACC2108/1274]CAT
containing a block mutation of the SRE; c versus p[ACC2108/266]TKCAT; d versus p[ACC2108/266]TKCAT containing a block
mutation of the SRE.
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levels, whereas Insig-2 mRNA levels were decreased by
41% (Fig. 4). CDCA had no effect on the abundance of
Insig-1 mRNA and Insig-2 mRNA after 6 and 12 h of
treatment. CDCA did not alter the abundance of SCAP
mRNA at any of the time points. The transient and op-
posing actions of CDCA on Insig-1 and Insig-2 expression
suggest that alterations in Insig expression play a minimal
role in mediating the effect of CDCA on mature SREBP-1
levels. Previous work has shown that bile acids increase
hepatic cholesterol levels (42, 45). This phenomenon
may mediate the inhibitory effect of CDCA on SREBP-1
processing by promoting the interaction between Insig
and SCAP-SREBP-1.
Effect of CDCA on the binding of nuclear hormone
receptor complexes to the ACCa LXRE/T3RE
On the basis of the observation that the ACCa LXRE/
T3RE was required for optimal inhibition of ACCa
transcription by CDCA, we hypothesized that the effect
of CDCA on ACCa transcription was mediated by alter-
ations in the binding of nuclear proteins to the ACCa
LXRE/T3RE. To investigate this possibility, gel mobility
shift analyses were performed using nuclear extracts from
chick embryo hepatocytes incubated with T0-901317 for
24 h followed by the addition of CDCA for various time
periods. We previously reported that the ACCa LXRE/
T3RE (2101 to286 bp) bound to four protein complexes
in nuclear extracts from chick embryo hepatocytes (29).
Three of these complexes (designated complexes 1, 2, and
3) contained LXR&RXR heterodimers, whereas the fourth
complex (designated complex 4) contained TR&RXR
heterodimers. In Fig. 5, we show that the ACCa LXRE/
T3RE bound to complex 1, complex 2, and complex 4
in nuclear extracts from hepatocytes incubated with T0-
901317 for 24 h. Complex 3 binding activity was not ob-
served in hepatocytes incubated under these conditions.
Addition of CDCA had no effect on the binding of com-
plexes 1, 2, and 3, suggesting that the inhibitory effect
of CDCA on ACCa LXRE activity was not attributable
to changes in the binding of LXR&RXR complexes to the
ACCa LXRE/T3RE. In support of this conclusion, CDCA
had no effect on the abundance of LXRamRNA in chick
embryo hepatocytes (Fig. 6). In contrast to the results for
complexes 1, 2, and 3, addition of CDCA decreased the
binding of complex 4 after 6, 12, and 24 h of treatment
(Fig. 5). This effect was associated with a reduction in the
expression of TRa mRNA in chick embryo hepatocytes
(Fig. 6). Because TR&RXR heterodimers repress tran-
scription in the absence of T3 (46), it is unlikely that
alterations in complex 4 binding activity mediate the
inhibitory effect of CDCA on T0-901317-induced ACCa
LXRE activity.
Effect of CDCA on histone acetylation of the ACCa
gene and the expression of SHP, PGC-1a, and
FGF-19 in avian hepatocytes
CDCA is a ligand for the nuclear hormone receptor
farnesoid X receptor (FXR) (47). FXR forms hetero-
dimers with RXR and binds DNA sequences [referred to
Fig. 4. CDCA suppresses the stimulatory effect of T0-901317 on
the concentration of mature sterol-regulatory element binding
protein-1 (SREBP-1). Chick embryo hepatocytes were isolated and
incubated in serum-free Waymouth’s medium containing insulin.
At 18 h of incubation, the medium was changed to one contain-
ing insulin and T0-901317. At 36 h of incubation, the medium
was replaced with one of the same composition. CDCA was added
to the medium at 42 h of incubation. After 2, 6, 12, and 24 h of
CDCA treatment, cellular extracts or total RNA were prepared.
The abundance of mature SREBP-1 in nuclear extracts and pre-
cursor SREBP-1 in membrane extracts was measured by Western
analyses. The abundance of mRNA encoding SREBP-1, insulin-
induced gene-1 (Insig-1), insulin-induced gene-2 (Insig-2), SREBP
cleavage-activating protein (SCAP), and ACCa was measured by
Northern analysis. Levels of mRNA or protein in cells treated with
CDCA for 0 h were set at 100, and the other values were adjusted
proportionately. Values are means 6 SEM of five experiments.
Asterisks indicate that the mean is significantly different (P, 0.05)
from that of cells incubated with CDCA for 0 h.
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as FXR response elements (FXREs)] that are distinct from
LXREs. FXREs are composed of two hexamers (consensus
AGGTCA) arranged as inverted repeats with 1 bp sepa-
rating the repeats. In the presence of CDCA, FXR&RXR
heterodimers activate genes involved in bile acid export,
bile acid conjugation, lipoprotein metabolism, and blood
clotting (reviewed in Ref. 47). In mouse hepatocytes,
CDCA-mediated activation of FXR&RXR heterodimers also
increases the transcription of SHP, an atypical member
of the nuclear receptor superfamily that lacks the ability
to bind DNA (42). Alterations in SHP expression play a
role in mediating the inhibitory effect of CDCA on the
transcription of cholesterol 7a-hydroxylase (CYP7A1), the
rate-limiting step in the bile acid synthesis pathway (48,
49). SHP interacts with liver receptor homolog-1 and
represses the ability of liver receptor homolog-1 to activate
CYP7A1 transcription. Other studies have shown that SHP
overexpression inhibits the ability of LXR to activate tran-
scription in transfection assays (50). To investigate the
role of SHP in mediating the inhibitory effect of CDCA
on LXR activation of ACCa, we determined whether
CDCA modulated the expression of SHP in chick embryo
hepatocytes. In contrast to the effect of CDCA on SHP
expression in mouse hepatocytes, CDCA caused a dose-
dependent decrease in the abundance of SHP mRNA
in chick embryo hepatocytes incubated with or without
T0-901317 (Fig. 6A, B). If SHP is a repressor of LXR ac-
tivity, then alterations in SHP expression do not mediate
CDCA regulation of ACCa transcription in chick em-
bryo hepatocytes.
Another factor that influences LXR activity is the level
of expression of the coactivator, PGC-1a (6, 51). Previous
studies have shown that activation of FXR causes a reduc-
tion in PGC-1a expression in mouse liver (52). This ob-
servation led us to investigate whether CDCA modulated
the expression of PGC-1a in chick embryo hepatocytes.
Addition of CDCA in the presence of T0-901317 caused a
rapid (<2 h), sustained (>24 h), and dose-dependent
decrease in the abundance of PGC-1a mRNA in chick
embryo hepatocytes (Fig. 6A, B). CDCA treatment also
decreased PGC-1a mRNA abundance in the absence of
T0-901317 (Fig. 6B). In contrast, CDCA treatment had
no effect on the abundance of the mRNA encoding the
related protein, PGC-1b. These observations are consis-
tent with a role of PGC-1a in mediating the effect of
CDCA on T0-901317-induced ACCa transcription.
PGC-1a activates transcription by recruiting histone
acetyltransferases (i.e., steroid receptor coactivator-1 and
CREB binding protein/p300) that modify the chromatin
of target promoters (53). To obtain further evidence that
alterations in PGC-1a expression play a role in mediating
the inhibitory effect of CDCA on ACCa LXRE, the extent
of histone acetylation in a region of chromatin encom-
passing the ACCa LXRE was measured using a ChIP assay.
Treatment of hepatocytes with CDCA reduced the acetyla-
tion of histone H3 and histone H4 at the ACCa LXRE
(Fig. 7). This observation is consistent with the inhibitory
effect of CDCA on PGC-1a expression. The decrease in
histone acetylation caused by CDCA may inhibit ACCa
Fig. 5. Effects of CDCA on the binding of nuclear receptor com-
plexes to the ACCa LXRE/T3 response element (T3RE). Chick
embryo hepatocytes were isolated and incubated in serum-free
Waymouth’s medium containing insulin. At 18 h of incubation, the
medium was changed to one containing insulin and T0-901317. At
36 h of incubation, the medium was replaced with one of the same
composition. CDCA was added to the medium at 42 h of incubation.
After 2, 6, 12, and 24 h of CDCA treatment, nuclear extracts were
prepared as described in Experimental Procedures. Nuclear extracts
were subjected to gel mobility shift analyses using an oligonucleotide
probe containing the ACCa LXRE/T3RE (2108 to 282 bp). Spe-
cific protein-DNA complexes are indicated by arrows. Previous stud-
ies have shown that complexes 1 and 2 contain LXR&retinoid X
receptor (RXR) heterodimers, whereas complex 4 contains TR&RXR
heterodimers (29). A: Data from a representative experiment. B:
Signals for complex 1, complex 2, and complex 4 were quantitated.
The binding activities of complex 1, complex 2, and complex 4 in
hepatocytes treated with CDCA for 0 h were set at 100, and the other
activities were adjusted proportionately. Values are means6 SEM of
four experiments. Asterisks indicate that the mean is significantly
different (P, 0.05) from that of cells incubated with CDCA for 0 h.
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LXRE activity by promoting chromatin condensation,
thereby limiting the access of DNA-bound LXR&RXR com-
plexes to the basal transcriptional machinery and other
transcriptional regulatory proteins. The effect of CDCA on
histone acetylation was sequence-specific, as CDCA had no
effect on histone acetylation at an uncharacterized region
of the SCD1 promoter (Fig. 7). Because of a lack of suit-
able antibodies, ChIP could not be performed to analyze
the recruitment of LXRa and PGC-1a to the ACCa gene.
Holt et al. (54) have identified an alternative pathway
through which natural and synthetic FXR agonists inhibit
CYP7A1 expression in human hepatocytes. In this path-
way, treatment with FXR agonists stimulates an increase in
the expression and secretion of FGF-19. This effect is
mediated by a FXRE in the FGF-19 gene. Secreted FGF-19
binds a cell surface receptor (fibroblast growth factor
receptor 4) and initiates a signaling cascade that results
in the activation of JNK and repression CYP7A1 transcrip-
tion. To assess the role of FGF-19 in mediating the in-
hibitory effect of CDCA on ACCa transcription, we first
determined whether CDCA modulated the expression
of FGF-19 in chick embryo hepatocytes. Treatment with
CDCA for 2 h stimulated a robust increase (7.8-fold) in
FGF-19 mRNA abundance (Fig. 6A). The stimulatory ef-
fect of CDCA on FGF-19 mRNA abundance was sustained
for at least 24 h of treatment and was dose-dependent
(Fig. 6A, B). We also determined whether the expression
of exogenous FGF-19 mimicked the effect of CDCA on
T0-901317-induced ACCa expression. Infection of chick
hepatocytes with a recombinant adenovirus containing
the chicken FGF-19 gene (AdEasy-FGF-19; 100 plaque-
forming units/cell) decreased T0-901317-induced ACCa
mRNA abundance by 36% relative to cells infected with
adenovirus lacking the chicken FGF-19 gene (AdEasy-
Null) (Fig. 8). These observations provide support for a
role of FGF-19 in mediating the effect of CDCA on ACCa
transcription. The exogenous FGF-19 mRNA expression
level (AdEasy-FGF-19; 100 plaque-forming units/cell) re-
quired to elicit a decrease in ACCa expression was higher
than the endogenous FGF-19 mRNA expression level
observed in hepatocytes treated with 75 mM CDCA. One
interpretation of this finding is that other processes in
addition to an increase in FGF-19 expression are involved
in mediating the inhibitory action of CDCA on ACCa ex-
pression. These processes may increase the sensitivity of
hepatocytes to FGF-19.
Fig. 6. Effects of CDCA on the expression of small het-
erodimer partner (SHP), peroxisome proliferator-activated
receptor g coactivator-1a (PGC-1a), PGC-1b, fibroblast
growth factor-19 (FGF-19), LXRa, and nuclear T3 re-
ceptor-a (TRa). A: Time course of CDCA action. Chick
embryo hepatocytes were isolated and incubated in serum-
free Waymouth’s medium containing insulin. At 18 h of
incubation, the medium was changed to one containing
insulin and T0-901317. At 36 h of incubation, the medium
was replaced with one of the same composition. CDCA
(75 mM) was added to the medium at 42 h of incubation.
After 2, 6, 12, and 24 h of CDCA treatment, total RNA was
prepared. The abundance of mRNA encoding SHP, PGC-
1a, PGC-1b, FGF-19, LXRa, and TRa was measured by
quantitative real-time PCR analysis. Levels of mRNA in
cells treated with CDCA for 0 h were set at 100, and the
other values were adjusted proportionately. Values are
means 6 SEM of five experiments. Asterisks indicate that
the mean is significantly (P , 0.05) different from that of
cells incubated with CDCA for 0 h. In cells treated with
CDCA for 2 h, the mean threshold cycle from quantitative
real-time PCR analysis of FGF-19 mRNA and ACCa mRNA
(100 ng of total RNA) was 17.2 and 17.8, respectively. The
mean threshold cycle for 18S RNA (1 ng of total RNA) was
16.5. B: The effects of CDCA on the expression of SHP,
FGF-19, and PGC-1a are dose-dependent. Chick embryo
hepatocytes were isolated and incubated in serum-free
Waymouth’s medium containing insulin. At 18 h of incu-
bation, the medium was changed to one of the same com-
position supplemented with or without T0-901317 in the
absence or presence of different concentrations of CDCA
(0–75 mM). After 28 h of treatment, the abundance of
SHP mRNA, FGF-19 mRNA, and PGC-1a mRNA was mea-
sured by Northern analysis. The data are representative of
four experiments.
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Role of ERK and p38 MAPK in mediating the regulation
of ACCa transcription by CDCA
In addition to JNK, there is evidence that other MAPK
signaling pathways are involved in mediating the actions
of bile acids on gene expression and cellular processes.
For example, bile acid induction of hepatic apoptosis and
LDL receptor expression is mediated by the activation of
p38 MAPK and ERK, respectively (55, 56). To investigate
the role of MAPKs in mediating the effect of CDCA on T0-
901317-induced ACCa transcription, we first determined
whether CDCA modulated the phosphorylation of amino
acid residues that control the activity of ERK, JNK, and
p38 MAPK. Treatment of chick embryo hepatocytes with
CDCA in the presence of T0-901317 (Fig. 9) or the ab-
sence of T0-901317 (data not shown) caused a rapid
(<5 min) and sustained (>24 h) increase in the phos-
phorylation of ERK (Tyr183/185), JNK (Thr183/Tyr185), and
p38 MAPK (Thr180/Tyr182). CDCA had a similar effect on
the phosphorylation of the upstream kinases for ERK
(MEK1/2) and p38 MAPK (MKK3/6) (Fig. 9). CDCA had
no effect on the concentration of total ERK, JNK, and
p38 MAPK. These findings indicate that CDCA stim-
ulates the activity of ERK, JNK, and p38 MAPK in chick
embryo hepatocytes.
We next determined the effects of cell-permeable inhib-
itors of MEK1/2 (U0126) and p38 MAPK (SB203580) on
the regulation of ACCa, PGC-1a, FGF-19, and SREBP-1 by
CDCA. Treatment of hepatocytes with U0126 or SB203580
suppressed the inhibitory effect of CDCA on T0-901317-
induced ACCa mRNA levels (Fig. 10A). This observation
suggests that the regulation of ACCa by CDCA requires
the presence of ERK and p38 MAPK. Treatment of hepa-
tocytes with SB203580 also suppressed the effects of CDCA
on the abundance of PGC-1a mRNA, FGF-19 mRNA, and
mature SREBP-1 protein (Fig. 10A, B). These findings are
consistent with the suggestion that p38 MAPK mediates
the effect of CDCA on ACCa transcription by modulat-
ing the expression of PGC-1a, FGF-19, and/or mature
SREBP-1. Treatment with U0126 also suppressed the effect
of CDCA on FGF-19 mRNA abundance but had no effect
on CDCA-induced changes in PGC-1a mRNA concentra-
tion and mature SREBP-1 levels. These observations are
consistent with the suggestion that ERK acts through the
FGF-19 signaling pathway in mediating CDCA regulation
of ACCa gene transcription. Results of experiments using
a selective inhibitor of JNK (SP600126) were inconclusive,
as this compound inhibited the induction of ACCamRNA
levels caused by T0-901317 (data not shown).
Fig. 7. CDCA decreases histone acetylation at the ACCa LXR
response unit. Chick embryo hepatocytes were isolated and
incubated in serum-free Waymouth’s medium containing insulin.
At 18 h of incubation, the medium was changed to one containing
insulin and T0-901317. At 36 h of incubation, the medium was
replaced with one of the same composition. CDCA was added to
the medium at 42 h of incubation. After 6 h of CDCA treatment,
the association of acetylated (Ac) histone H3 and acetylated his-
tone H4 with ACCa and SCD1 genomic sequences was measured.
Chromatin immunoprecipitation (ChIP) assays were performed as
described in Experimental Procedures. Immunoprecipitates were
analyzed by PCR using primers that flanked the LXR response unit
(LXRU) of ACCa promoter 2 and an uncharacterized region of the
SCD1 promoter. The regions of the ACCa gene and the SCD1 gene
that were amplified by PCR are indicated at the top. Chromatin
samples that were processed in parallel without the application
of primary antibody (No Ab) served as controls. The input lanes
show the results of PCR using chromatin samples taken before the
immunoprecipitation step. Results are representative of four inde-
pendent experiments.
Fig. 8. FGF-19 mimics the inhibitory effect of CDCA on ACCa
expression. Chick embryo hepatocytes were isolated and incubated
in Waymouth’s medium lacking hormones. At 4 h of incubation,
the medium was changed to one containing T0-901317 and insulin,
and recombinant adenovirus [10–100 plaque-forming units (Pfu)/
cell] was added at this time. At 24 h of incubation, the medium
was replaced with one containing T0-901317 and insulin with or
without CDCA. At 48 h of incubation, the cells were harvested
and total RNA was isolated. The abundance of ACCa mRNA and
FGF-19 mRNA was measured by quantitative real-time PCR analysis.
The level of mRNA in cells treated without adenovirus and CDCA
was set at 1, and the other values were adjusted proportionately.
Values are means 6 SEM of four experiments. Significant dif-
ferences (P , 0.05) between means are indicated by the asterisks.
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To investigate whether the CDCA-mediated activation
of p38 MAPK was dependent on ERK, we determined the
effect of U0126 on the phosphorylation of p38 MAPK. In-
hibition of ERK by U0126 had no effect on the ability
of CDCA to stimulate the phosphorylation of p38 MAPK
(Fig. 10C). We also demonstrated that inhibition of p38
MAPK by SB203580 had no effect on the ability of CDCA
to stimulate the phosphorylation of ERK. These results
indicate that activation of p38MAPK by CDCA is not linked
to the activation ERK and vice versa. This finding is con-
sistent with the observation that CDCA-induced changes
in the expression of PGC-1a andmature SREBP-1 are sensi-
tive to p38 MAPK inhibition but not to ERK inhibition.
We next compared the effects of different bile acids on
the phosphorylation of p38MAPK andERK and the expres-
sion of ACCa mRNA, SREBP-1 mRNA, mature SREBP-1
protein, PGC-1a mRNA, and FGF-19 mRNA in chick
embryohepatocytes incubatedwithT0-901317.As observed
above, incubating hepatocytes with CDCA in the presence
ofT0-901317 for 24h stimulated a5.5- to 7.1-fold increase in
the phosphorylation of ERK and p38 MAPK, respectively
(Fig. 11A). Treatment with cholic acid also increased the
phosphorylation of ERK and p38 MAPK, but the extent of
this effect (2.3- to 2.8-fold) was less than that observed
for CDCA. Treatment with deoxycholic acid also caused a
small increase (1.8-fold) in the phosphorylation of p38
MAPK but not ERK. Treatment with ursodeoxycholic acid,
taurocholic acid, hyodeoxycholic acid, and taurodeoxy-
cholic acid had no effect on the phosphorylation of ERK
and p38 MAPK. Of the bile acids tested, only CDCA
was effective at inhibiting the expression of ACCa mRNA,
PGC-1a mRNA, and mature SREBP-1 protein and increas-
ing the expression of FGF-19 mRNA (Fig. 11B). Thus, bile
acids that were not effective at stimulating the activity of
p38 MAPK and ERK were also not effective at regulating
the expression of ACCa mRNA, FGF-19 mRNA, PGC-1a
mRNA, and mature SREBP-1.
This observation provides further support for the pro-
posal that the CDCA-mediated changes in the expression
of ACCa, FGF-19, and PGC-1a require the activation of
ERK and/or p38 MAPK. The inability of cholic acid and
deoxycholic acid to modulate the expression of ACCa
mRNA, FGF-19 mRNA, PGC-1a mRNA, and mature
SREBP-1 protein may be attributable to the fact that cho-
lic acid and deoxycholic acid stimulate a smaller increase
in the phosphorylation of ERK and p38 MAPK than CDCA
or that activation of ERK and p38 MAPK is necessary but
not sufficient to mediate changes in the expression of
ACCamRNA, FGF-19 mRNA, PGC-1amRNA, and mature
SREBP-1 protein caused by CDCA. Why CDCA is more
effective than other bile acids at modulating ERK and p38
MAPK phosphorylation is not known. One possible mech-
anism may involve variations in the transport of different
bile acids across the cell membrane. The results of this
experiment comparing the effects of different bile acids
also demonstrate that alterations in ACCa expression are
tightly correlated with changes in the expression of ma-
ture SREBP-1 protein, FGF-19 mRNA, and PGC-1amRNA.
This observation provides further support for a role of
SREBP-1, FGF-19, and PGC-1a in mediating CDCA regula-
tion of ACCa gene transcription.
DISCUSSION
Previous studieshave shown that activationof theCDCA/
FXR signaling pathway modulates triglyceride synthesis in
intact animals. For example, oral administration of CDCA
Fig. 9. CDCA increases the phosphorylation of extracel-
lular signal-regulated kinase (ERK), c-Jun N-terminal
kinase (JNK), and p38 mitogen-activated protein kinase
(MAPK) in chick embryo hepatocytes incubated with T0-
901317. Chick embryo hepatocytes were isolated and in-
cubated in serum-free Waymouth’s medium containing
insulin. At 18 h of incubation, the medium was changed
to one containing insulin and T0-901317. At 36 h of incu-
bation, the medium was replaced with one of the same
composition. CDCA was added to the medium at 42 h of
incubation. After 5, 15, 30, 45, and 60 min and 2, 6, 12, and
24 h of CDCA treatment, total cell lysates were prepared.
Western analyses were performed using antibodies against
phosphorylated p38 MAPK (Thr180/Tyr182), phosphory-
lated ERK (Tyr183/185), phosphorylated JNK (Thr183/
Tyr185), phosphorylated Raf (Ser259), phosphorylated
MAPK kinase 3/6 (MKK3/6) (Ser189/207), phosphorylated
MAPK/ERK kinase (MEK1/2) (Ser221), total p38 MAPK,
total ERK, and total JNK. The data shown are from a rep-
resentative experiment. This experiment was repeated two
times with similar results.
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Fig. 10. Inhibition of ERK and/or p38 MAPK suppresses the effects of CDCA on the expression of ACCa,
SREBP-1, PGC-1a, and FGF-19. Chick embryo hepatocytes were isolated and incubated in serum-free
Waymouth’s medium containing insulin. At 18 h of incubation, the medium was changed to one containing
insulin and T0-901317. At 30 h of incubation, the medium was replaced with one of the same composition.
At 42 h of incubation, SB203580 (20 mM), U0126 (20 mM), or DMSO (vehicle) was added to the culture
medium. CDCA (75 mM) was added to the culture medium at 43 h of incubation, and the incubation was
continued for 6 h. Cells were harvested and total RNA and cellular extracts were prepared. A: ACCamRNA,
PGC-1a mRNA, and FGF-19 mRNA were measured by quantitative real-time PCR. The level of mRNA in
cells treated with T0-901317 and vehicle was set at 1, and the other values were adjusted proportionately.
Percentage inhibition or fold increase by CDCA was calculated for cells treated with vehicle, SB203580, or
U0126. Values were calculated for individual experiments and then averaged. The results are means6 SEM
of five experiments. Asterisks indicate that the mean is significantly different (P , 0.05) from that of cells
treated with vehicle. B: The abundance of mature SREBP-1 in nuclear extracts was measured by Western
analysis. Top: A representative immunoblot. Bottom: Signals for mature SREBP-1 were quantitated, and
the percentage inhibition by CDCA was calculated for cells treated with vehicle, SB203580, or U0126. The
results are means 6 SEM of four experiments. The asterisk indicates that the mean is significantly different
(P, 0.05) from that of cells treated with vehicle. C: The abundance of phosphorylated ERK, phosphorylated
p38 MAPK, total ERK, and total p38 MAPK in total cell lysates was measured by Western analysis. These data
are representative of three independent experiments.
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reduces hypertriglyceridemia and hepatic triglyceride
secretion in hamsters fed a high-fructose diet (41). Treat-
ment with CDCA also attenuates hypertriglyceridemia in
patients with gallstone disease (40). Further support for an
inhibitory effect of CDCA/FXR signaling on triglyceride
production is derived from knockout mouse studies dem-
onstrating that disruption of the FXR gene causes an in-
crease in triglyceride levels in the blood and liver (45). The
results of the present study indicate that CDCA inhib-
its triglyceride production, at least in part, by acting directly
on the liver to decrease the expression of enzymes that
constitute the de novo fatty acid synthesis pathway.
One of the key findings of this study is that treat-
ment with CDCA inhibits the activation of lipogenic
enzyme expression caused by the LXR agonist T0-901317
(Figs. 1, 2) and that the mechanism mediating the effect
of CDCA on ACCa transcription involves a decrease in
the activity of the LXRE in promoter 2 of the ACCa gene
(Fig. 3). What is the mechanism by which CDCA inhibits
the activity of the ACCa LXRE? Results from DNA bind-
ing studies indicate that the CDCA-mediated decrease in
ACCa LXRE activity is not attributable to changes in the
binding of protein complexes to the ACCa LXRE (Fig. 5).
The reduction in ACCa LXRE activity is also not the result
of an increase in expression of the LXR repressor SHP, as
CDCA decreases the abundance of SHP mRNA in chick
embryo hepatocytes (Fig. 6). We propose that CDCA in-
hibits ACCa LXRE activity, at least in part, by decreasing
the expression of the LXR coactivator PGC-1a. In support
of this proposal, the CDCA-mediated reduction in ACCa
mRNA abundance in chick embryo hepatocytes is pre-
ceded or paralleled by a decrease in the concentration of
PGC-1a mRNA and the acetylation of histone H3 and
histone H4 at the ACCa LXRE (Figs. 6, 7). Further support
for this proposal is derived from the observation that the
pattern of regulation of PGC-1a mRNA by different bile
acids is similar to that of ACCa mRNA (Fig. 11). The ob-
servation that FXR activation decreases PGC-1a expression
in mice (52) raises the possibility that alterations in PGC-
1a expression also play a role in mediating the effects of
CDCA on hepatic lipogenic enzyme expression in mam-
malian species.
In addition to the ACCa LXRE, a SRE located imme-
diately downstream of the ACCa LXRE plays a role in
mediating the inhibitory effects of CDCA on T0-901317-
induced ACCa transcription in chick embryo hepato-
cytes. Previous work has shown that this SRE enhances the
ability of the ACCa LXRE to activate ACCa transcription
in the presence of T0-901317 (15). In the present study, we
show that CDCA inhibits the LXR accessory function of
the ACCa SRE and that the mechanism mediating this
effect involves a decrease in mature SREBP-1 concentra-
tion (Figs. 3, 4). We also demonstrate that CDCA regulates
the concentration of mature SREBP-1 at a posttranslation-
al step. Previous work has shown that CDCA decreases the
expression of SREBP-1c in mouse hepatocytes (42). Thus,
alterations in SREBP-1 activity appear to play a role in
mediating the effects of CDCA on lipogenic enzyme ex-
pression in both rodents and avians.
Fig. 11. Effects of different bile acids on the phosphorylation of
ERK and p38 MAPK and the expression of ACCa, SREBP-1, PGC-
1a, and FGF-19. Chick embryo hepatocytes were isolated and
incubated in serum-free Waymouth’s medium containing insulin.
At 18 h of incubation, the medium was changed to one contain-
ing insulin and T0-901317. At 30 h of incubation, the medium was
replaced with one of the same composition. At 42 h of incuba-
tion, CDCA, cholic acid (CA), deoxycholic acid (DCA), ursode-
oxycholic acid (UDCA), taurocholic acid (TCA), hyodeoxycholic
acid (HDCA), or taurodeoxycholic acid (TDCA) was added to the
culture medium, and the incubation was continued for 6 h. The
concentration of all bile acids was 75 mM. Cells were harvested, and
total RNA and cell lysates were prepared. A: The abundance of
phosphorylated ERK, phosphorylated p38 MAPK, total ERK,
and total p38 MAPK in total cell lysates was measured by Western
analysis. These data are representative of three independent ex-
periments. B: ACCa mRNA, SREBP-1 mRNA, PGC-1a mRNA, and
FGF-19 mRNA weremeasured by quantitative real-time PCR. Mature
SREBP-1 protein was measured by Western analysis. The level of
mRNA or protein in cells treated in the absence of bile acids was
set at 1, and the other values were adjusted proportionately. The
results are means 6 SEM of three experiments. Asterisks indicate
that the mean is significantly different (P , 0.05) from that of any
other treatment.
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As in avian hepatocytes, CDCA inhibits the stimulatory
effects of LXR agonists on lipogenic enzyme expression
in mouse hepatocytes (42, 57) and rat hepatocytes (S.
Bhatnagar and F. B. Hillgartner, unpublished data). In
mouse and rat hepatocytes, CDCA increases the expres-
sion of SHP mRNA (42, 58). Based on this finding and the
observation that overexpression of SHP in cell lines re-
presses the LXR activation of transfected target promoters,
Watanabe et al. (42) have proposed that alterations in SHP
expression mediate the inhibitory effects of CDCA on he-
patic lipogenic gene transcription. In agreement with this
proposal, Watanabe et al. (42) have shown that ablation of
the SHP gene in mice abolishes the inhibitory effect of
FXR agonists on hepatic SREBP-1c expression. Although
this observation clearly demonstrates that SHP is required
for CDCA regulation of lipogenic enzyme expression, data
from a study by Boulias et al. (59) indicate that an increase
in SHP expression does not initiate the CDCA response.
Boulias et al. (59) have shown that transgenic expression
of SHP at physiological levels stimulates the hepatic ac-
cumulation of triglycerides and the expression of mRNAs
encoding ACCa, FAS, SCD1, and SREBP-1c. Such a find-
ing suggests that an increase in SHP expression promotes
an increase rather than a decrease in hepatic lipogenesis.
Furthermore, based on ChIP analyses, Boulias et al. (59)
have shown that SHP is not associated with the promoter/
regulatory region of the SREBP-1c gene and the FAS gene
in livers of wild-type mice and transgenic mice expressing
SHP. This observation indicates that the mechanism by
which SHP controls hepatic lipogenic gene transcription
does not involve interactions of SHP with LXR or other
regulatory proteins on lipogenic gene promoters. The re-
sults of the present study demonstrating that CDCA in-
hibits ACCa transcription in the absence of an increase in
SHP expression provide further evidence that an increase
in SHP expression is not involved in mediating the effects
of CDCA on lipogenic enzyme expression. Further ex-
perimentation is needed to determine how SHP partici-
pates in the CDCA regulation of lipogenic genes.
FGF-19 and its mouse ortholog, FGF-15, are potent in-
hibitors of CYP7A1 gene transcription in liver (54, 60).
Results from experiments using FGF-15 knockout mice
indicate that FGF-15 plays a critical role in mediating the
inhibitory effect of FXR agonists on hepatic CYP7A1 ex-
pression (60). In human hepatocyte cultures, CDCA ac-
tivates the expression of FGF-19 via a FXR-dependent
mechanism (54). Accordingly, FGF-19 secreted by the liver
has been proposed to function in an autocrine or para-
crine manner to mediate the inhibitory effect of CDCA on
hepatic CYP7A1 transcription. In intact mice, oral admin-
istration of FXR agonists induces the expression of FGF-15
in the small intestine but has no effect on the expression
of FGF-15 in liver (60). Thus, FGF-15 secreted by the small
intestine has been proposed to function in an endocrine
manner to mediate the feedback regulation of hepatic
CYP7A expression by FXR agonists. In the present study,
we show that CDCA induces the expression of FGF-19 in
chick embryo hepatocytes and that ectopic expression of
chicken FGF-19 in chick embryo hepatocytes mimics the
inhibitory effect of CDCA on T0-901317-induced expres-
sion of ACCa. We postulate that FGF-19 plays a role in
mediating the effect of CDCA on the expression of ACCa
and other lipogenic enzymes. In support of this proposal,
Tomlinson et al. (61) and Fu et al. (62) have shown that
administration of recombinant human FGF-19 or trans-
genic expression of the human FGF-19 gene in obese/
diabetic mice causes a reduction in serum and hepatic
triglyceride levels. Treatment of obese/diabetic mice with
FGF-19 also decreases fat accumulation in adipose tissue
and enhances insulin sensitivity. These effects of FGF-19
on adipose tissue and insulin sensitivity may be attributed,
in whole or in part, to a reduction in hepatic lipogenic
enzyme expression, as increased rates of hepatic fatty acid
synthesis contribute to enhanced adipose stores and in-
sulin resistance in obese/diabetic animal models (63).
Interestingly, activation of FXR with CDCA or knockdown
of hepatic ACCa expression with antisense oligonucleo-
tides modulates hepatic triglyceride levels, adiposity, and
insulin sensitivity in a manner similar to that observed with
FGF-19 treatment (41, 64, 65). This observation provides
further support for a role of FGF-19 in mediating the re-
gulation of lipogenic enzyme expression by CDCA.
In contrast to the inhibitory effect of CDCA on the T0-
901317-induced expression of lipogenic enzyme mRNAs
in avian and rodent hepatocytes, CDCA has no effect or
enhances T0-901317-induced expression ABCA1 mRNA
(Fig. 1) (S. Bhatnagar and F. B. Hillgartner, unpublished
data) (42). Previous studies have shown that SREBP binds
to an E-box element in the ABCA1 promoter and sup-
presses ABCA1 gene transcription via an undefined
mechanism (66). We postulate that the lack of an inhib-
itory effect of CDCA on ABCA1 transcription is attribut-
able to the CDCA-mediated reduction in mature SREBP-1
levels, resulting in a derepression of the ABCA1 promoter.
Such an effect would counteract the inhibitory action of
CDCA on ligand-activated LXR&RXR complexes bound to
the ABCA1 promoter.
Another finding of the present study is that p38 MAPK
and ERK play a role in mediating the inhibitory action
of CDCA on ACCa expression. CDCA activates p38 MAPK
and ERK, and pharmacological inhibition of p38 MAPK
and ERK suppresses the ability of CDCA to inhibit T0-
901317-induced ACCa expression (Figs. 9, 10). Inhibition
of p38 MAPK and/or ERK also suppresses the effects of
CDCA on the expression of potential mediators of CDCA
action, such as mature SREBP-1, PGC-1a, and FGF-19.
Thus, p38 MAPK and ERK may regulate lipogenic enzyme
expression by controlling the expression of these regula-
tory factors. In support of a role of p38 MAPK inmediating
the effect of CDCA on hepatic lipogenic gene expression,
Xiong et al. (67) recently showed that activation of p38
MAPK with a constitutively active form of MKK6 inhibits
the expression of FAS and SREBP-1c in rat hepatocytes.
Interestingly, glucagon and polyunsaturated fatty acids
also inhibit the hepatic expression of glucose-6-phosphate
dehydrogenase, FAS, and SREBP-1c via a mechanism
that is dependent on the presence of p38 MAPK and/or
ERK (67–69). Thus, p38 MAPK and ERK appear to have a
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general role in inhibitory pathways controlling lipogenic
gene expression.
In addition to changes in gene expression, the activity
of PGC-1a is controlled at the posttranslational level. Fan
et al. (70) have shown that p160 Myb binding protein
(p160 MBP) binds to PGC-1a, causing a repression PGC-
1a activity, and that the phosphorylation of PGC-1a by
p38 MAPK disrupts this interaction, resulting in a de-
repression/activation of PGC-1a activity. Phosphorylation
of PGC-1a by p38 MAPK mediates the stimulatory effects
of b-adrenergic agonists on uncoupling protein-1 gene
transcription and does so by increasing the ability of PGC-
1a to coactivate the peroxisome proliferator-activated re-
ceptor a (PPARa) on the uncoupling protein-1 promoter
(71, 72). These findings are inconsistent with our data
demonstrating that p38 MAPK mediates the inhibitory
effect of CDCA on LXR agonist-induced ACCa expression.
One explanation for this discrepancy is that the effect of
p160 MBP binding on PGC-1a activity varies depending
on the nature of the nuclear receptor that interacts with
PGC-1a. In support of this possibility, Oberkofler and col-
leagues (6, 72) have shown that the binding of p160 MBP
to PGC-1a inhibits the ability of PGC-1a to coactivate
PPARa but has no effect on the ability of PGC-1a to co-
activate LXR and PPARg. The molecular basis for the
different effects of p160 MBP on PGC-1a coactivation of
PPARa, PPARg, and LXR may be attributable to differ-
ences among these nuclear receptors in their site of inter-
action on the PGC-1a molecule (6, 72).
In summary, we show that CDCA suppresses the stim-
ulatory effects ofT0-901317on the secretionof triglycerides
and the expression of lipogenic enzymes in hepatocytes.
Thus, activation of the CDCA signaling pathway represents
a potential therapeutic approach to counteract the unde-
sired effects of LXR agonists on triglyceride levels in the
blood and liver. As the stimulatory effect of T0-901317 on
hepatic ABCA1 expression is not inhibited by CDCA, we
postulate that the antiatherosclerotic action of LXR
agonists is not diminished by CDCA. Additional studies
are needed to assess the effects of CDCA and other FXR
agonists on the development of atherosclerosis in animal
models of obesity and diabetes.
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